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Abstract
Development of hypertension is influenced by genes, environmental effects and their interactions,
and the human metabolome is a measurable manifestation of gene-environment interaction. We
explored the metabolomic antecedents of developing incident hypertension in a sample of African
Americans, a population with a high prevalence of hypertension and its comorbidities. We
examined 896 (565 females, aged 45–64 years) African American normotensives from the
Atherosclerosis Risk in Communities (ARIC) Study, whose metabolome was measured in serum
collected at the baseline examination and analyzed by high throughput methods. The analyses
presented here focus on 204 stably measured metabolites over a period of 4–6 weeks. Weibull
parametric models considering interval censored data were used to assess the hazard ratio for
incident hypertension. We used a modified Bonferroni correction accounting for the correlations
among metabolites to define a threshold for statistical significance (p<3.9×10−4). During 10-years
of follow-up, 38% of baseline normotensives developed hypertension (N=344). With adjustment
for traditional risk factors and estimated glomerular filtration rate, each +1-standard deviation
difference in baseline 4-hydroxyhippurate, a product of gut microbial fermentation, was associated
with 17% higher risk of hypertension (p=2.5×10−4), which remained significant after adjusting for
both baseline systolic and diastolic blood pressure (p=3.8×10−4). After principal component
analyses, a sex steroids pattern was significantly associated with risk of incident hypertension
(highest versus lowest quintile hazard ratio, 1.72; 95% CI, 1.05 to 2.82; p for trend=0.03), and
stratified analyses suggested that this association was consistent in both genders. Metabolomic
analyses identify novel pathways in the etiology of hypertension.
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Hypertension is a leading risk factor for cardiovascular disease mortality, causing more than
7 million deaths every year worldwide.1 African Americans have greater prevalence and
severity of hypertension than European-Americans,2 and are, thus, prime candidates for
primary prevention efforts. Hypertension and its underlying pathophysiology may be present
for years before clinical diagnosis, when irreversible pathology has already occurred.
Current clinical evaluation of hypertension risk, such as blood pressure measurement,
provides limited insight into relevant abnormal mechanisms for a particular patient. Because
blood pressure is regulated and hypertension is controlled by a multiple physiologic and
anatomic systems,3 it has been proposed that a “systems-biology” approach to hypertension
risk management and control would be beneficial.4 The metabolome represents the outcome
of multiple physiologic and metabolic processes and the ultimate downstream expression of
the interaction between gene action and environmental exposure.5, 6 Therefore, the
metabolome may provide a high-resolution, multifactorial phenotypic signature of the
etiology, manifestation, or pathophysiology7 of hypertension.
To date, no study has explored the metabolomic antecedents of incident hypertension in
African-Americans, who have the highest prevalence and rate of incident hypertension
among all races.2 Therefore, we measured the metabolome in a well-characterized sample of
African-Americans from the Atherosclerosis Risk in Communities (ARIC) Study and
identified individual metabolites and metabolite patterns that are significantly associated
with incident hypertension during approximately 10-years of follow-up.
Methods
Study Sample
The ARIC Study consists of a prospective cohort designed to identify the causes and
outcomes of cardiovascular diseases. The ARIC study population was selected as a
probability sample of 15,792 men and women aged 45 to 64 years from 4 communities
(Forsyth County, NC; Jackson, MS; suburbs of Minneapolis, MN; and Washington County,
MD). Detailed descriptions of its study design, objectives and procedures have been
published elsewhere.8 Eligible participants were interviewed at home and then invited to a
baseline clinical examination between 1987 and 1989. Participants returned for multiple
follow-up clinical examinations. The ARIC Study was approved by the institutional review
boards at each site. Metabolomic profiles were measured in a subsample of ARIC African
American participants (N=1,977) randomly selected from the Jackson, MS field center from
all of those who provided informed consented for genetic research, provided quality dietary
data, and fasted ≥8 hours before the baseline exam.
Assessment of Baseline Covariates and Metabolites
The baseline examinations included standardized medical history, physical examination with
anthropometric measures, and laboratory testing. Sitting blood pressure was measured by
trained technicians on the left arm of the participants with an appropriately sized cuff three
times with a random-zero mercury sphygmomanometer after a 5-minute rest, and the
average of the last two readings was used. Hypertension was defined as systolic blood
pressure (SBP) ≥140 mmHg or diastolic blood pressure (DBP) ≥90 mmHg or currently
taking anti-hypertensive medication. Incident hypertension was defined as new occurrences
of hypertension during the follow-up examinations among the baseline normotensives.
Leisure-time physical activity was measured using a modification of the Baecke Physical
Activity questionnaire.9 Alcohol intake was ascertained from a standardized questionnaire
and the alcohol amount in grams per week was used in these analyses. Cigarette smoking
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status was self-reported and categorized as current and noncurrent smoker. Diabetes was
defined as a fasting glucose level ≥7.0 mmol/L, a nonfasting level ≥11.1 mmol/L, a self-
reported physician diagnosis, or pharmacologic hypoglycemic treatment. Estimated
glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) equation.10
Among all normotensive participants (N=927) at the baseline examination, 31 were
excluded from the analysis because of either prevalent coronary heart disease (by history or
ECG criteria, N=23), prevalent heart failure (by Gothenburg criteria or heart failure
medication use,11 N=12), or prevalent stage 4 or 5 chronic kidney disease (eGFR <30 mL/
min/1.73 m2,12 N=1) leaving 896 normotensive participants (males, N=331) for the analyses
presented here.
Detection and quantification of metabolites in fasting serum samples continuously stored at
−80° was completed by Metabolon Inc. (Durham, USA) using an untargeted, gas
chromatography-mass spectrometry and liquid chromatography-mass spectrometry (GC-MS
and LC-MS)-based metabolomic quantification protocol. Metabolites were identified by
comparison to library entries of purified standards or recurrent unknown entities.11 This
untargeted approach identified and quantified 602 metabolites, including named compounds
whose chemical identity is known (N=361; 90 in amino acid metabolism pathways, 16 in
carbohydrate, 12 in cofactors and vitamins, 8 in energy, 147 in lipid, 14 in nucleotide, 29 in
peptide and 45 in xenobiotics), as well as unnamed compounds that do not currently have a
chemical standard (N=241).13 The unknown chemical identities are tagged beginning with
“X” and followed by numbers, such as “X-12345”. Measurement methods of these
metabolites and rigorous laboratory quality control process were described in detail
elsewhere.11 A repeatability study was carried out to evaluate the biologic stability of
metabolites in fasting serum collected 4–6 week apart. Based on these analyses, 204 out of
total 602 metabolites were selected based on having a reliability coefficient ≥0.6 as well as
having fewer than 80% of the values below the detection limit or missing (BDL/missing),11
and these values were assigned the lowest detected value for that metabolite in all samples.
These 204 metabolites consisted of 187 metabolites treated as continuous variables in the
analyses (<50% BDL/missing observations; 108 named and 79 unnamed compounds), and
17 metabolites treated as ordinal variables in the analyses (50–80% BDL/missing
observations; 1= BDL/missing values, 2= values below the median, and 3= values equal or
above the median; 10 named and 7 unnamed compounds) (supplement table S1).
For descriptive analyses across groups, Chi-square tests were used for categorical variables,
and two-sample t-tests or Wilcoxon’s rank-sum tests were used for continuous traits. The
Weibull parametric model for interval censored data, which is an accelerated-failure time
proportional-hazards model,14 was used to estimate the hazard ratio (HR) of developing
incident hypertension. Two multivariable models were used to assess the relation between
metabolites (either an individual metabolite or metabolomic pattern) and incident
hypertension. Covariates were selected based on published reports.15–18 The basic model
(Model 1) adjusted for traditional risk factors, i.e., age, gender, leisure-time physical
activity, alcohol intake, current cigarette smoking status, body mass index (BMI) and
diabetes status. Model 2 included the covariates in Model 1 with the additional of a measure
of kidney function, i.e., eGFR. For the identified individual metabolomic biomarker
candidates and the potential hypertension-related principal-components, we also investigated
whether the observed association was robust to further adjustment for baseline SBP and
DBP.
In analyses of association between an individual metabolite and hypertension, all HRs were
calculated and reported per +1-SD for the continuous variables or per +1-category change in
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the categorical variables. A modified stepwise Bonferroni procedure, the Dubey/Armitage-
Parmar algorithm11, 19 was used to correct for multiple comparisons and a significance level
of 3.9×10−4 (2 tailed) was considered for each individual test. This adjustment takes into
account the full correlation matrix of metabolites and uses the mean correlation among the
metabolites in the formula, where the new α-level for the kth hypothesis for k=1,2,…, K is
readjusted for each individual metabolites according to: αk = 1 − (1 − α)1/mk, where mk =
K1−r.k, , and rjk is the correlation coefficient between the jth and kth
metabolites. When the average of the correlation coefficients is zero, this adjustment is
according to the Bonferroni procedure and when it is one, the adjusted and the unadjusted p-
values are the same.
Metabolites are expected to be correlated in complex ways. Thus, a principal-components
analysis (PCA) was used to group the 187 metabolites into metabolomic patterns. The three
patterns retained were selected based on three criteria: 1) the Kaiser criterion (eigenvalues
>1), 2) inflection point of the scree plot, and 3) the interpretability of the patterns. 20, 21 A
factor score for each study participant was calculated from the sum of the levels from all the
187 metabolites, multiplied by their respective factor loadings. Metabolomic patterns were
named according to the metabolite groups loading highest on each of the three factor
patterns: sex steroids, alpha amino acids and branch-chain amino acids (supplement table
S2). The scores for each PCA-derived pattern were entered separately into the Weibull
parametric models. HR of developing incident hypertension for the highest versus lowest
quintile of these three patterns, as well as the corresponding p value for trend across
quintiles were calculated in all analyses. For the PCA analyses, a significance level of 0.05
(2 tailed) was used.
All statistical analyses were performed in SAS version 9.2 (SAS Institute, Cary, NC).
Results
During the approximate 10-year follow-up period, 38.4% of the 896 normotensives at
baseline (N=344; 39.3% of the female and 36.9% of the male normotensives) developed
hypertension (incidence rate: 63.94 per 1000 person-years; median 7.67 years to first
diagnosis of hypertension), and 209 reported having begun antihypertensive medications.
Participants who developed hypertension were more likely to weigh more, be diabetic, and
have higher SBP and DBP at the baseline examination (Table 1). The median and
interquartile range for the percentage of BDL/missing values for the 204 metabolites
included in our analysis were 2.6% and 20.4%, respectively.
The metabolite 4-hydroxyhippurate was consistently associated with incident hypertension
across models (HR per SD=1.17 and 1.18 respectively in Model 1 and 2, p<3.9×10−4, Table
2), suggesting its association with hypertension may be independent of kidney function. The
adjusted HR per SD for 4-hydroxyhippurate also remained significant after adjusting for
baseline blood pressure (HR per SD, 1.18; 95% CI, 1.08 to 1.29; p=3.8×10−4; Table 2). No
other metabolite was significantly associated with incident hypertension (supplement table
S1).
Principal component analyses yielded three biologically plausible metabolomic patterns: sex
steroids, alpha amino acids and branch-chain amino acids (Table 3). The first pattern, sex
steroids, was statistically significantly associated with incident hypertension in both models
and the other two patterns were uniformly not significant (Table 3). Stratified analysis
suggested a consistent association of the sex steroids pattern with incident hypertension in
both males and females (in males, highest versus lowest quintile HR=1.93; in females,
highest versus lowest quintile HR=1.50). With further adjustment for baseline SBP and
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DBP, the significance of the sex steroids pattern was slightly attenuated (highest versus
lowest quintile HR, 1.40; 95% CI, 0.84 to 2.32; p for trend in quintile number =0.10; Figure
1). To assess whether the association ascribed to sex steroids pattern was driven by one or a
few metabolites, individual metabolites composing the sex steroids pattern were assessed.
Three metabolites, epiandrosterone sulfate, 5alpha-androstan-3beta 17beta-diol disulfate and
androsterone sulfate were nominal significant predictors of incident hypertension (Table 2).
It is of note that the variance of the metabolites explained by the three PCA-derived patterns
was relatively low (17%), which is believed to be a result of the pathway diversity of the
human metabolome.
Discussion
We prospectively examined a sample of middle-aged African American normotensives
having serum metabolomic data. After adjustment for traditional risk factors and kidney
function, each SD increment of baseline 4-hydroxyhippurate was associated with an 18%
higher risk of hypertension, which remained significant after adjusting for baseline blood
pressure. In addition, a sex steroids pattern derived from principal components analysis was
also associated with elevated risk of incident hypertension (highest versus lowest quintile
HR=1.72; p for trend in quintile number =0.03). To our knowledge, our study is among the
first to study human serum metabolomic antecedents of hypertension in a well-defined
prospective cohort setting. Although there is limitation in our study such as a limited sample
size and lack of availability of an independent replication sample, our findings provide
potential novel biomarkers associated with incident disease independently of traditional risk
factors, and hold promise for better defining the underlying pathophysiology of
hypertension.
4-Hydroxyhippurate is an end product of benzoate metabolism from microbial fermentation
of polyphenols.22 It may also originate in the oxidative break-down of many exogenous
benzenoid substances by detoxifying enzymes in the endoplasmic reticulum or
microsomes.23, 24 In the cardiovascular system, oxidative stress plays a critical physiological
role in controlling endothelial function, vascular tone, and cardiac function in hypertension.3
Therefore, we speculate that its mechanism of action on blood pressure regulation may be
through a multitude of pathways such as gut microbial fermentation and/or oxidative
stress.23–27
A sex steroids pattern was positively and independently associated with incident
hypertension after adjustment for traditional risk factors. This pattern may reflect the
catabolism of pregnenolone, and the subsequent metabolism of its estrogen and androgen
derivatives. It is not prudent to promote firm conclusions regarding the role of progesterone
in hypertension,28 though it may lead to hypertension via the body’s response to stress.29 Of
note, stress may have a more important effect on hypertension in African Americans than
other groups.30, 31 For estrogens and androgens, a balance between activation mechanisms
of vasoconstriction32–35 and vasorelaxation36, 37 determines the net effect on vascular tone
and blood pressure.38 The mechanisms by which sex steroids affect blood pressure involve
direct effects on vascular, renal and heart cells, indirect effects mediated by humoral
factors,28 as well as modifying aldosterone, renin and aldosterone to renin ratio.39 Our
findings provide further insight into important questions regarding the role of sex hormones
in hypertension, though further research is required.
Enhancing the ability to identify high-risk individuals for developing hypertension is
particularly important, because proven, preventive therapies exist, end-organ complications
accrue over time and the whole process can be delayed. Our prospective cohort study
detected biomarkers of hypertension well before the onset of apparent clinical condition.
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The strength of our study includes a population-based prospective cohort with detailed
clinical characterization, and the strict quality standards11 to ensure valid and reliable
inference with a single measurement.
The candidate metabolites of interest from this study should be measured in an independent
replication sample of African Americans before further application. The present study is
among the largest to date and the first prospective cohort to explore serum metabolite
profiles in hypertension. High-throughput metabolomics, like other –omic technologies,
brings a danger of generating false-positive associations due to multiple comparisons and
over-fitting. Application of traditional statistical approaches (e.g., Bonferroni correction)
without taking into account the correlations among metabolites may levy an insurmountable
statistical penalty that can obscure biologically relevant associations (i.e. false negative
results).40 The modified Bonferroni procedure used in this study considers the full
correlation matrix among metabolites, which should preserve statistical power and minimize
false negative results. Clearly, the sources of variation underlying the human metabolome
are varied, and the ability to predict incident hypertension after years of follow-up is
influenced by many factors including biologic characteristics of the metabolites, study
design, and laboratory factors.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Previous studies suggested that targeting high-risk, normotensive individuals for
treatment may delay hypertension onset, allow earlier implementation of intervention
measures, thereby possibly mitigating vascular complications.41 The extra information
from metabolomic studies may help target such individuals, and potentially improve the
sensitivity and specificity of the final algorithm for prediction of hypertension. The
present study identified potential single metabolomic biomarker (i.e. 4-hydroxyhippurate)
as well as a metabolomic pattern (i.e. sex steroids) independently pointing to
dysregulated metabolic pathways underlying hypertension. The findings in this study
may impact clinical care by allowing scarce resources to be concentrated on those at
greatest risk of hypertension. In addition, an early indicator of hypertension may indicate
earlier therapeutic interventions that could minimize the likelihood of serious
complications.
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Novelty and Significance: 1) What Is New, 2) What Is Relevant?
1. What Is New? (the novelty)
• One metabolite, 4-hydroxyhippurate and a sex steroids pattern (consisting of
pregnenolone and its estrogen and androgen derivatives) were identified as
independent predictors of incident hypertension among African Americans by
untargeted high-through metabolomic profiling protocol.
2. What Is Relevant? (how the study relates to hypertension)
• Metabolomic studies may help target individuals of high risk in hypertension,
and indicate earlier therapeutic interventions to them when necessary.
3. Summary (the conclusions of the study)
• The present work is the first studying metabolomic antecedents of hypertension
in African Americans, who have the highest rates of hypertension among all
races. It shows that metabolomic biomarkers of hypertension can be detected
well before the onset of the clinical condition.
Zheng et al. Page 10














Hazard ratios and 95% CIs of incident hypertension by quintiles of the sex steroids pattern at
baseline from Weibull parametric models. Model 2 was adjusted for age, gender, leisure-
time physical activity, current cigarette smoking status, alcohol intake, prevalent diabetes,
body mass index, and estimated glomerular filtration rate. Compared to the quintile of the
lowest scores for the sex steroids pattern, only the quintile of the highest scores had a
significant higher risk of incident hypertension, but the trend of associations across quintiles
was statistically significant (p<0.05). In the “Model 2+BP” model, baseline systolic blood
pressure and diastolic blood pressure were added, and the effects of the sex steroid pattern
were attenuated.
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Table 1
Distribution of baseline risk factors by incident hypertension status among normotensives at baseline
Characteristics Normotensive atbaseline (N=896) Non-incident hypertension (N=552) Incident hypertension (N=344)
Age, y 51.47 ± 5.4 51.40 ± 5.5 51.59 ± 5.3
Male, n (%) 331 (36.9) 209 (37.9) 122 (35.5)
Leisure-time physical activity* 2.13 ± 0.6 2.13 ± 0.6 2.13 ± 0.6
Current cigarette smoking, n (%) 258 (28.8) 165 (29.9) 93 (27.0)
Ethanol intake in grams/week, median
(IQR)
0.0 (0.0–13.2) 0.0 (0.0–13.2) 0.0 (0.0–13.2)
BMI, kg/m2† 28.65 ± 5.5 28.09 ± 5.3 29.55 ± 5.8
Prevalent diabetes, n (%)‡ 97 (10.8) 47 (8.5) 50 (14.5)
eGFR, mL/min/1.73 m2 107.35 ± 15.6 107.46 ± 15.4 107.18 ± 15.9
SBP, mmHg† 116.70 ± 11.1 114.01 ± 10.8 121.02 ± 10.2
DBP, mmHg† 74.70 ± 7.8 73.38 ± 7.8 76.83 ± 7.2
BMI indicates body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; IQR, interquartile range; SBP, systolic
blood pressure.
For continuous variables except “ethanol intake in grams/week”, mean values ± standard errors are shown. Percentages for categorical variables are
shown in parentheses.
*
2.13 was interpreted as “moderate active”42 based on the tertile distribution of the leisure-time physical activity score (low active: <2.00,
moderate active: 2.00–2.49, high active: ≥2.50) among the current study participants.
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